Subarachnoid Hemorrhage, Aneurysmal
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
ADELKorea - Seoul
1 programMultimodality Monitoring Directed Management of Aneurysmal Subarachnoid HaemorrhageN/A1 trial
Active Trials
Verona PharmaUK - London
1 programStandard management according to international/national guidelinesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Verona PharmaStandard management according to international/national guidelines
ADELMultimodality Monitoring Directed Management of Aneurysmal Subarachnoid Haemorrhage
Clinical Trials (2)
Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group
Start: May 2021Est. completion: Dec 2028
N/ARecruiting
Multimodality Monitoring Directed Management of Aneurysmal Subarachnoid Haemorrhage
Start: Feb 2017Est. completion: Feb 2022
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials
2 companies competing in this space